

Can RSV and combos relieve the industry's long suffering COVID problem?

LONDON, UK----27th March 20225----ExpertREACT.

Revenues from new respiratory vaccines such as COVID-19 and more recently, RSV are causing wide fluctuations in the total industry market size. New respiratory combinations are also a large part of vaccine R&D with the first product (flu/COVID-19) the first in line for USA regulatory consideration. Many could follow....

Now that the reporting season is over **VacZine Analytics** has calculated FY2024 revenues from 10 major vaccine players* (developed markets only). We estimate these companies netted **~\$55bn** in revenues in 2024, an **\$8.8bn** reduction on the FY2023 figure of **\$63bn**. More striking is that the FY2024 figure is roughly half the amounts we previously estimated in FY2021 (~\$96bn) and FY2022 (~\$100bn). Clearly much momentum, especially in COVID-19 vaccines, has been lost as global markets switched away from bulk pandemic purchasing to targeted 'at risk' endemic vaccination. The FY 2024 figure is, however, **+\$22bn** (+67%) over the pre-pandemic FY2020 figure of **~\$33bn** suggesting some underlying growth the industry.

In this article **VacZine Analytics** investigates recent trends in the industry, with a focus on RSV and respiratory vaccines.....

The full article is **free of charge** to new subscribers and/or followers. Please contact us for the full article at info@vaczine-analytics.com

Keywords: ABRYSVO®, AREXVY®, mRESVIA®, Beyfortus®, clesrovimab, mRNA-1083, mRNA-1283

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vaczine-analytics.com

VacZine Analytics® is a trading division of Assay Advantage Ltd, UK Company No. 5807728

Copyright. All Rights Reserved, 2025

